Verum for Epidermolysis Bullosa
This trial will test if a new drug can be safely and effectively used to treat a rare skin condition called Recessive Dystrophic Epidermolysis Bullosa (RDEB).
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Has Verum attained the necessary regulatory clearance from the FDA?
"According to our evaluation, verum has been awarded a safety rating of 3 due its successful completion of Phase 3 trials and the collected data illustrating efficacy."
Are researchers still enrolling participants for this investigation?
"As per the information listed on clinicaltrials.gov, this trial is not currently enrolling participants. The study was first posted June 1st 2023 and last updated April 20th 2023. At present there are 24 other trials actively recruiting individuals for their studies."